The role of regional chemotherapy in the management of extremity soft tissue malignancies

被引:10
作者
Smith, H. G. [1 ]
Hayes, A. J. [1 ]
机构
[1] Royal Marsden Hosp NHS Fdn Trust, Sarcoma & Melanoma Unit, Acad Dept Surg, London, England
来源
EJSO | 2016年 / 42卷 / 01期
关键词
Isolated limb perfusion; Isolated limb infusion; In-transit melanoma; Soft tissue sarcoma; ISOLATED LIMB PERFUSION; TUMOR-NECROSIS-FACTOR; MERKEL CELL-CARCINOMA; TERM-FOLLOW-UP; FACTOR-ALPHA; INTERFERON-GAMMA; ADVANCED MELANOMA; PHASE-I; INTRAARTERIAL TEMOZOLOMIDE; HYPERTHERMIC PERFUSION;
D O I
10.1016/j.ejso.2015.08.165
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Regional chemotherapy involves the targeted delivery of high dose chemotherapy to an affected area. In the limbs, the two main methods employed are isolated limb perfusion (ILP) and isolated limb infusion (ILI), with advantages and disadvantages to each technique. The aim of this review was to clarify the roles of each technique in the management of locally advanced soft tissue malignancies of the extremities. Methods: Relevant articles were identified from a comprehensive literature search using the PubMed database. Keywords included isolated limb perfusion, isolated limb infusion, in-transit melanoma and sarcoma. No restrictions on publication date were used. Results: Regional chemotherapy may be used to secure local control in a range of soft tissue malignancies not amenable to standard excision and is increasingly used as an induction treatment in soft tissue sarcoma. Though both ILI and ILP are well established in the management of in-transit melanoma, ILP should be preferentially used in soft tissue sarcoma. Conclusion: Regional chemotherapy is an effective treatment for locally advanced extremity malignancies and the technique used should be tailored to patient and tumour factors. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:7 / 17
页数:11
相关论文
共 92 条
[31]  
Giles Mitchell H, 2013, Cancer Manag Res, V5, P243, DOI 10.2147/CMAR.S45746
[32]   Tumor Vascularization and Histopathologic Regression of Soft Tissue Sarcomas Treated With Isolated Limb Perfusion With TNF-α and Melphalan [J].
Grabellus, Florian ;
Kraft, Corinna ;
Sheu-Grabellus, Sien-Yi ;
Bauer, Sebastian ;
Podleska, Lars E. ;
Lauenstein, Thomas C. ;
Poettgen, Christoph ;
Konik, Margarethe J. ;
Schmid, Kurt W. ;
Taeger, Georg .
JOURNAL OF SURGICAL ONCOLOGY, 2011, 103 (05) :371-379
[33]   Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: A series of patients surgically treated at a single institution [J].
Gronchi, A ;
Casali, PG ;
Mariani, L ;
Lo Vullo, S ;
Colecchia, M ;
Lozza, L ;
Bertulli, R ;
Fiore, M ;
Olmi, P ;
Santinami, M ;
Rosai, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (07) :1390-1397
[34]   Extremity Soft Tissue Sarcoma in a Series of Patients Treated at a Single Institution Local Control Directly Impacts Survival [J].
Gronchi, Alessandro ;
Lo Vullo, Salvatore ;
Colombo, Chiara ;
Collini, Paola ;
Stacchiotti, Silvia ;
Mariani, Luigi ;
Fiore, Marco ;
Casali, Paolo Giovanni .
ANNALS OF SURGERY, 2010, 251 (03) :506-511
[35]   The palliative value of tumor necrosis factor α-based isolated limb perfusion in patients with metastatic sarcoma and melanoma [J].
Grunhagen, DJ ;
de Wilt, JHW ;
Graveland, WJ ;
van Geel, AN ;
Eggermont, AMM .
CANCER, 2006, 106 (01) :156-162
[36]   TNF-based isolated limb perfusion in unresectable extremity desmoid tumours [J].
Grünhagen, DJ ;
de Wilt, JHW ;
Verhoef, C ;
van Geel, AN ;
Eggermont, AMM .
EJSO, 2005, 31 (08) :912-916
[37]   REGIONAL HYPERTHERMIC PERFUSION WITH MELPHALAN AFTER SURGERY FOR RECURRENT MALIGNANT-MELANOMA OF THE EXTREMITIES [J].
HAFSTROM, L ;
RUDENSTAM, CM ;
BLOMQUIST, E ;
INGVAR, C ;
JONSSON, PE ;
LAGERLOF, B ;
LINDHOLM, C ;
RINGBORG, U ;
WESTMAN, G .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (12) :2091-2094
[38]  
HANSSON J, 1987, CANCER RES, V47, P2631
[39]   Isolated limb perfusion with melphalan and tumor necrosis factor α for advanced melanoma and soft-tissue sarcoma [J].
Hayes, Andrew J. ;
Neuhaus, Susan J. ;
Clark, Matthew A. ;
Thomas, J. Meirion .
ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (01) :230-238
[40]  
Huang J, 2001, CANCER, V92, P172, DOI 10.1002/1097-0142(20010701)92:1<172::AID-CNCR1306>3.0.CO